trending Market Intelligence /marketintelligence/en/news-insights/trending/cH6fqI1466mufoWU8quItQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

MacroGenics seeks US FDA approval for breast cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

MacroGenics seeks US FDA approval for breast cancer drug

Rockville, Md.-based MacroGenics Inc. filed an application with the U.S. Food and Drug Administration for approval of margetuximab to treat certain breast cancer patients.

SNL Image

The company's biologics license application of margetuximab is for treating previously treated patients with HER2-positive breast cancer whose cancer has spread to other organs of the body, in combination with chemotherapy.

The application is supported by data from a late-stage study, dubbed Sophia, which showed that patients receiving the combination experienced a slower progression of the disease compared to Roche Holding AG's Herceptin, or trastuzumab. The combination was also better in shrinking the size of the tumors.

Margetuximab is an investigational monoclonal antibody, designed to block HER2, which can propagate the growth of cancer cells, and enhance the engagement of the immune system.